EOFlow Co., Ltd., a provider of wearable drug delivery solutions, has announced that its wholly owned US subsidiary, EOFlow Inc. has signed an agreement to establish a joint venture in the US with the UK biotech firm Zihipp Limited, a spin out from Imperial College London.
Also Read: Kolon Tissuegene Resumes TG-C Phase III Studies in the US
The new venture named SanPlena will focus on developing a family of gut-hormone analogues that promise rapid and dramatic weight loss without the common side effects seen with other such agents delivered via daily or weekly injection. Proprietary formulation of the analogues optimizes them for continuous subcutaneous delivery thus allowing the drug dosing to be tailored to a particular patient’s metabolism, speeding weight loss while avoiding adverse effects from over-dosing. EOFlow will provide an initial funding and its EOPatch wearable drug delivery platform while Zihipp provides its proprietary peptide analogues and clinical support for SanPlena. EOFlow’s founding CEO, Jesse J. Kim, will assume the role as the founding CEO of SanPlena while the rest of the executive team will be rounded out by senior staff from both Zihipp and EOFlow.
Zihipp is a UK biotech firm which spun out from Imperial College London in 2012. Led by the highly respected Prof. Sir Stephen R. Bloom and a world-class research team, the company develops peptide hormones to combat soaring rates of diabetes and obesity. Prof. Sir Stephen R. Bloom is one of the world’s leading obesity experts and his research has focused on the gut hormones which control appetite and metabolism. He is well known as a seminal figure in creation of the hormone-based diabetes and obesity treatment market. Professor Sir Stephen Bloom is the head of Drug Development, Department of Metabolism, Digestion & Reproduction at Imperial College London and director of research for North West London Pathology at Imperial College Healthcare NHS Trust, serving six major acute hospitals.
Zihipp has developed several new peptide drug candidates optimized for obesity and NASH (Non-Alcoholic Steatohepatitis) treatment analogous to appetite suppressing hormones such as oxyntomodulin and peptide YY which have been proven through clinical trials. These analogues have been optimized for continuous subcutaneous delivery to avoid the common side effects associated with daily or weekly injection of similar agents. SanPlena aims to leverage the advantages of EOFlow’s wearable, digital healthcare platform to realize the promise of these agents in driving rapid and dramatic weight loss; up to 15% of one’s weight within 2-3 months.